Clinical trials
Phase 1/2 Muscular Dystrophy, Duchenne trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Unknown status | 9 |
| Recruiting | 6 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sarepta Therapeutics, Inc. | 5 |
| BioMarin Pharmaceutical | 4 |
| Chaitanya Hospital, Pune | 2 |
| Cooperative International Neuromuscular Research Group | 2 |
| Craig McDonald, MD | 2 |
| Entrada Therapeutics, Inc. | 2 |
| Kevin Flanigan | 2 |
| Solid Biosciences Inc. | 2 |
| AO GENERIUM | 1 |
| Acibadem University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Dystrophy, Duchenne | 45 |
| Muscular Dystrophies | 6 |
| Muscular Diseases | 2 |
| Neuromuscular Diseases | 2 |
| Cardiomyopathies | 1 |
| Muscular Dystrophies, Limb-Girdle | 1 |
| Muscular Dystrophy, Facioscapulohumeral | 1 |
| Musculoskeletal Diseases | 1 |
| Nervous System Diseases | 1 |
| Obesity | 1 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.